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SUMMARY – Polytrauma is a term describing patients with injuries involving multiple body 
regions that compromises function of the body and/or organ involved. Th e aim of the study was to 
evaluate the potential role of erythropoietin in predicting poorer outcome in trauma patients. Th is 
prospective study included 86 patients admitted to the Emergency Center of Serbia due to polytrau-
ma assigned according to Injury Severity Score (ISS). Th e patients were further evaluated using the 
Acute Physiology and Chronic Health Evaluation II and Sequential Organ Failure Assessment scores 
and erythropoietin levels. Th ere was a signifi cant diff erence among erythropoietin levels at admission, 
after 48 and 72 hours, and on day 7 of hospital stay, with signifi cantly higher levels in patients with 
ISS values 49-75. Based on the results, ROC curves were used to identify cut-off  levels to predict ISS 
score with critical clinical course. It was concluded that erythropoietin could be a good marker of in-
jury severity. Further research has to be performed to determine the cut-off  values of erythropoietin 
that are signifi cant for injury severity.
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Introduction
Patients with polytrauma are one of the greatest 
challenges faced by physicians1. Polytrauma is a term 
describing patients with multiple injuries that involve 
several parts of the body and compromise function of 
the body and/or organ involved1-3. Th e most popular 
and most commonly used defi nition of trauma is based 
on the Injury Severity Score (ISS)2,4,5. Another defi ni-
tion that is also appropriate describes it as injury to at 
least two body regions with Abbreviated Injury Scale 
(AIS) ≥3 and with the presence of systemic infl amma-
tory response syndrome (SIRS) on at least one day 
during the fi rst 72 hours1,5. Appropriate triage and op-
timization of treatment approach in such patients is 
one of the key factors that infl uence fi nal outcome in 
these patients1,6,7. Treatment of patients with polytrau-
ma requires plenty of resources and eff ort, multiple 
surgeries, prolonged stay at intensive care unit, and 
complex rehabilitation programs1,2,7. Mortality in pa-
tients with polytrauma varies from 9% to 48%, de-
pending on age group, extent of injuries, other comor-
bidities, and appropriate triage5,6,8-10.
Furthermore, it is very important to timely evaluate 
treatment outcome in patients with polytrauma5. As of 
today, many prognostic factors have been developed5. 
Erythropoietin, a glycoprotein predominantly synthe-
sized in the kidneys, plays the central role in stimula-
tion of erythropoiesis, but also has other purposes, 
such as cytoprotective, anti-apoptotic, anti-infl amma-
tory and antioxidant activity11,12. Studies have shown 
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that the administration of erythropoietin before or af-
ter stressful event that led to cell ischemia protects 
cells from development of ischemic sequels13. Erythro-
poietin has a vast therapeutic potential in patients with 
polytrauma. Studies have shown that the use of eryth-
ropoietin is useful in posttraumatic anemia triggered 
by systemic infl ammatory response that is present in 
polytrauma14. Also, therapeutic properties of erythro-
poietin have already been used in septic shock, endo-
toxemia, hemorrhagic shock, spinal cord trauma and 
multiple organ trauma15.
Patients and Methods
Th is prospective study included patients admitted 
to the Emergency Center, Clinical Center of Serbia 
during the period from October 2016 to March 2017 
because of polytrauma. Polytrauma was defi ned based 
on the ISS score4. In order to consider critical patients 
only, the study included patients with ISS score 25 or 
higher16. Th e study included a total of 86 patients who 
were further assigned to one of two groups: group 1 
with ISS score 25-48 and group 2 with ISS score 49-
7516. Th e exclusion criteria were pregnancy, treatment 
with erythropoietin products, hematologic condition, 
malignant diseases, and failure to obtain consent for 
participation in the study. Th e following clinical vari-
ables were collected: age, sex, cause of injury, preexist-
ing chronic disease, length of hospital stay, outcome, 
blood pressure, mean arterial pressure (MAP), heart 





tio, neurologic status (Glasgow Coma Scale, GCS), as 
well as the amount of transfusions administered to the 
patient. Th e causes of injury covered by the study were 
traffi  c injuries, fall from height, and other (including 
fi rearm injuries and explosions). Prior chronic condi-
tions were divided into 5 groups: heart failure, liver cir-
rhosis, epilepsy, renal failure and angina pectoris.
Th e length of hospital stay was classifi ed into two 
groups: up to 7 days and more than 7 days. At admis-
sion, on day 2, day 3 and day 7, all patients underwent 
laboratory evaluation using the following tests: white 
blood cell count (WBC), platelet count, hematocrit, 
aspartate aminotransferase (AST), alanine amino-
transferase (ALT), gamma-glutamyltransferase (GGT), 
serum electrolyte levels, creatinine, international 
 normalized ratio (INR), prothrombin time, albumin, 
C-reactive protein (CRP), venous lactate and total 
bilirubin.
Furthermore, erythropoietin levels were measured 
at admission, 24 and 72 hours following admission, 
and on day 7. Th e patients were further evaluated based 
on the Acute Physiology and Chronic Health Evalua-
tion II (APACHE II) and Sequential Organ Failure 
Assessment (SOFA) scores that were calculated at ad-
mission and on days 2, 3 and 7. APACHE II score was 
calculated from the patient’s age and the following 12 
parameters: PaO
2
, temperature, MAP, arterial pH, 
heart rate, respiratory rate, sodium, potassium, creati-
nine, hematocrit, leukocyte count and GCS17. Infor-
mation regarding previous health status, including 
prior surgeries, history of organ insuffi  ciency or im-
munocompromised state, was calculated into the re-
sult17. Th e conventional SOFA score was calculated 









)18. Th e evaluation was also 
performed based on erythropoietin levels in group 1 
and 2 patients. Furthermore, we calculated cut-off  lev-
els of erythropoietin in predicting higher ISS score, i.e. 
in predicting which patients had more complicated 
polytrauma and required additional resources and care 
during their further treatment.
Statistical analyses were performed using the SPSS 
22.0 (SPSS Inc., Chicago, IL, USA) software. Th is 
study protocol complied with ethical principles of the 
Declaration of Helsinki of 1975, as revised in 1983, 
and was approved by the Ethics Committee of the 
Clinical Center of Serbia. For normal variables, means 
and standard deviations were calculated. χ2test and in-
dependent sample t-test were used to assess diff erences 
Table 1. Patient demographic characteristics






(min 16; max 88)
Cause 
of injury:
Traffi  c accident 54 (62.8%)




Heart failure 12 (60%)
Liver cirrhosis 2 (10%)
Epilepsy 2 (10%)
Renal failure 2 (10%)
Angina pectoris 2 (10%)
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Table 2. Patient clinical characteristics
Duration of 
hospitalization
Up to 7 days 16 (34.8%)
More than 7 days 30 (65.2%)
Outcome:




















ISS = Injury Severity Score; APACHE II = Acute Physiology and 
Chronic Health Evaluation II; SOFA = Sequential Organ Failure 
Assessment
Table 3. Demographic and clinical data on patients classifi ed into two groups based 












Length of hospital stay
Up to 7 days 8 8
<0.001




Fatal outcome 0 8
Transfusion 4413.3 3317.1 0.320
Table 4. APACHE II score in group 1 and 2 patients
APACHE II score Group 1 Group 2 p value
Day 1 16.5±6.8 33.6±18.7 <0.001
Day 2 16.4±9.4 34.9±25.1 <0.001
Day 3 15.3±8.1 37.1±22.4 <0.001
Day 7 13.9±6.1 15.0±0.0 0.739
APACHE II = Acute Physiology and Chronic Health Evaluation II
Table 5. SOFA score in group 1 and 2 patients
SOFA score Group 1 Group 2 p value
Day 1 12.5±3.3 15.8±3.3 0.002
Day 2 12.2±2.8 17.5±3.8 <0.001
Day 3 11.9±3.1 18.4±4.4 <0.001
Day 7 11.0±2.1 13.5±1.7 0.022
SOFA = Sequential Organ Failure Assessment
between the groups. Th e values of p<0.05 were consid-
ered statistically signifi cant. Th e performance of eryth-
ropoietin in predicting higher ISS score was analyzed 
by calculating area under the receiver operating char-
acteristics curves (AUROC). Th e best cut-off  points 
were identifi ed based on the ROC curves.
Results
Tables 1 and 2 show demographic and clinical 
characteristics of patients. Th e study included 86 pa-
tients. Th ere were three times more male than female 
patients (74.4% vs. 25.6%). Th e patient mean age was 
48, range 16-88 years. Th e most common cause of in-
jury was traffi  c accident accounting for 62.8% of pa-
tients. Among prior chronic conditions, heart failure 
was common (n=12). In most patients, the length of 
hospital stay was more than 7 days (65.2%) and the 
outstanding majority of patients survived (89.5%).
Table 2 shows mean ISS, APACHE II and SOFA 
score and erythropoietin levels. Th e patients received a 
mean of 2598.5 mL of transfusion (Table 2).
Table 3 shows demographic data broken down by 
patient groups based on ISS score. Th e mean age in 
groups 1 and 2 was 50 and 33 years, respectively, and 
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the diff erence between the two groups was signifi cant 
(p=0.003). Group 1 had more patients who stayed at 
the hospital for more than 7 days (p<0.001). Th e num-
ber of patients who survived was signifi cantly higher 
in group 1 than in group 2 (66 vs. 2), yielding a highly 
signifi cant diff erence (p<0.001).
APACHE II scores measured on days 1, 2 and 3 
were signifi cantly higher in group 2 (p<0.001), as il-
lustrated in Table 4.
SOFA score calculated on days 1, 2, 3 and 7 of hos-
pital stay was signifi cantly higher in group 2 (Table 5).
Th ere was a signifi cant diff erence between erythro-
poietin levels at admission, after 48 and 72 hours, and 
on day 7 of hospital stay. Signifi cantly higher levels 
were found in group 2, as shown in Table 6.
Based on signifi cantly higher erythropoietin levels 
recorded in group 2, we plotted ROC curves that were 
further used to identify the cut-off  levels to predict ISS 
score of 48-75 (Fig. 1). Table 7 shows erythropoietin 
cut-off  levels, together with sensitivity and specifi city, 
as well as AUROC values.
Discussion
Th e term “polytrauma” signifi es injuries to at least 
two body regions that are life-threatening1. In the <40 
age group, its incidence is 44.9% and it is the most 
common cause of death. Th e mortality and morbidity 
rates and functional recovery are directly aff ected by 
professional and timely care2,3. Appropriate triage and 
optimization of treatment approach in such patients is 
one of the key factors that aff ect fi nal outcome in these 
patients1,6,7. Treatment of patients with polytrauma re-
quires plenty of resources and eff orts, multiple surger-
ies, prolonged stay at the intensive care unit, and com-
plex rehabilitation programs considering the course of 
the disease is complicated by sepsis, anemia and multi-
organ dysfunction1,2,7.
Our study showed a predominance of male pa-
tients (74.4% of males vs. 25.6% of females), which is 
in accordance with other studies that examined this 
subject19-23.
Th e mean age of patients included in this study was 
48.1, which is in accordance with the study by Berber 
et al.24, whereas another study conducted by Hyder et 
al. in Pakistan showed a somewhat younger population 
with as many as 51.1% of patients aged from 20 to 
3923. Furthermore, a study by Tosounidis et al. showed 
the mean patient age of 38.425.
Table 6. Erythropoietin levels in group 1 and 2 patients
Erythropoietin Group 1 Group 2 p value
Admission 32.5±32.4 100.5±67.4 <0.001
24 h 39.3±76.4 69.3±64.3 0.204
48 h 15.5±27.2 56.8±64.5 0.001
72 h 12.7±20.3 46.2±52.4 <0.001
Day 7 7.1±8.1 16.4±8.4 0.001






Sensitivity Specifi city AUROC
Admission 42.3 80% 81.8% 0.836
48 h 11.9 100% 72.7% 0.895
72 h 11.3 100% 71.8% 0.923
Day 7 8.3 100% 71.8% 0.891
AUROC = area under the receiver operating characteristics curve 
Fig. 1. Receiver operator curve (ROC).
EPO = erythropoietin
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Th e most common cause of injuries in our study 
were traffi  c accidents (62.8%), while the second most 
common cause were falls from height (30.2%). Th e 
study by Hyder et al. demonstrated a somewhat lower 
incidence of traffi  c injuries (51.1%) and falls from 
height (17.5%)23.
It was observed that heart failure was the most 
common prior condition in our patients. Th is fact 
could be explained by heart failure being a complicated 
disease with high morbidity and mortality rates, af-
fecting many physical and mental abilities of patients, 
thus making trauma common in this population26.
Th ere were twice more patients who stayed at the 
hospital for more than 7 days, accounting for 65% of 
all patients. Paydar et al. report on average length of 
hospitalization of 7.4 days, with maximum duration of 
21 days27. Abedzadeh-Kalahroudi et al. compared the 
length of hospital stay between a group of patients 
having returned to their work and a group that could 
not return to their place of work after trauma. In the 
group of patients who did return to their place of work 
after trauma, most of them had the length of hospital 
stay of 1-6 days. In the other group, hospital stay of 
more than 6 days prevailed28.
Th e mean ISS score in patients from our study was 
40.5, signifying that the majority of patients had com-
plicated polytrauma and that these patients were most 
commonly in severe condition and required extensive 
eff orts for their treatment, both in terms of resources 
and staff 16.
Th e mean volume of transfusion received by the 
patients was 2598.5 mL. Optimal timing and volume 
of transfusion is diffi  cult to determine, but it is some-
thing that a clinician should always bear in mind be-
cause studies have shown that the larger the volume of 
transfusion, the higher is the likelihood of some of the 
transfusion related adverse sequels, such as infection, 
acute lung injury, acute kidney injury, and thromboem-
bolic events29,30. Furthermore, there could be other 
complications, such as reperfusion injury, vasoconstric-
tion, infl ammation, or impaired immune reaction29.
Considering demographic and clinical characteris-
tics of patients assigned to diff erent groups based on 
their ISS score, it is seen that the second group (with 
more severe injuries) involved younger population, 
more fatal outcomes and longer hospital stay. Similar 
results were obtained by Reihani et al., whose study, 
similar to ours, showed traffi  c injuries as the major 
cause of polytrauma and larger proportion of young 
males with more serious injuries31.
Erythropoietin levels at admission, 48 and 72 hours 
and 7 days following admission were signifi cantly high-
er in the population of patients with ISS score 49-75. 
Th e explanation may lie in the fact that the patients 
with ISS score 49-75 had severe polytrauma and that 
they were in very critical condition with multiple inju-
ries, various complications and more severe overall con-
dition compared to patients from the group with ISS 
score 25-48. Studies performed to date dealing with this 
subject have shown that many tissues produce and lo-
cally release erythropoietin in response to hypoxic, bio-
chemical and physical stress. Erythropoietin protects 
tissue from ischemia and reperfusion injury, it has anti-
apoptotic eff ect and promotes tissue regeneration11-14,32. 
We also used erythropoietin to predict whether the pa-
tient would be assigned to group 2 according to ISS 
score. Erythropoietin proved best at 72 hours following 
admission, with 11.3 cut-off  value, 100% sensitivity, 
71.8% specifi city, and AUROC value of 0.923.
Following the above mentioned, we conclude that 
larger amounts of erythropoietin are produced and re-
leased in more severely traumatized patients, which 
should be a subject of further investigations aimed at 
determining which group of patients would benefi t 
more from treatment with erythropoietin. We also 
showed that erythropoietin could also have good char-
acteristics in predicting the severity of polytrauma.
Based on the results of our study, we conclude that 
erythropoietin appears to be a good marker of injury 
severity. Further research has to be performed to deter-
mine the cut-off  values of erythropoietin that are sig-
nifi cant for injury severity.
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Sažetak
ERITROPOETIN U PROCJENI ISHODA LIJEČENJA KOD BOLESNIKA S POLITRAUMOM
V. Arsenijević, A. Šijački, I. Marjanović, D. Micić, V. Nikolić, A. Veljković, P. Popović, S. Stanković i V. Jeremić
Politrauma je termin koji opisuje bolesnike s povredama koje uključuju više dijelova tijela i koje ugrožavaju funkciju  tijela 
i/ili organa. Cilj studije je bio procijeniti potencijalnu ulogu eritropoetina u predviđanju lošeg ishoda kod bolesnika s poli-
traumom. Ova prospektivna studija obuhvatila je 86 bolesnika koji su primljeni u Urgentni centar Srbije zbog politraume 
dijagnosticirane prema rezultatu težine povreda (Injury Severity Score, ISS). Bolesnici su dalje procijenjeni pomoću rezultata 
Akutnog fi ziološkog bodovnog sustava i bodovnog sustava kronične procjene zdravlja II. te procjene insufi cijencije organa i 
razine eritropoetina. Postojala je značajna razlika između razine eritropoetina kod prijma, poslije 48 i 72 sata te sedmog dana 
boravka u bolnici, sa znatno višim razinama kod bolesnika s vrijednostima ISS 49-75. Na osnovi rezultata krivulje ROC su 
primijenjene za identifi kaciju graničnih vrijednosti kako bi se predvidio rezultat ISS s kritičnim kliničkim tijekom. Zaklju-
čeno je da eritropoetin može biti dobar pokazatelj ozbiljnosti povreda. Potrebno je daljnje istraživanje za određivanje granič-
nih vrijednosti eritropoetina koje su značajne za ozbiljnost povreda.
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